Japanese patients with diabetic macular edemas were treated with intravitreal ranibizumab and reported predictors of good clinical outcomes, which included better baseline best-corrected visual acuity and a reduced central retinal thickness; hence, this supports the early use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) for DMEs [65]. The gene discussed is VEGFA; the disease is diabetic macular edema.